Optiscan has been featured in Manufacturer’s Monthly following the announcement of a five-year exclusive collaboration with US-based Long Grove Pharmaceuticals to accelerate FDA submissions and expand clinical applications of its real-time imaging technology.

The article outlines how the agreement will integrate Long Grove’s FDA-approved contrast agent, AK-FLUOR®, with Optiscan’s advanced endomicroscopic imaging systems—including the InVue® surgical device—initially focusing on breast surgery. The collaboration is expected to extend into gastrointestinal, robotic, and laparoscopic procedures, with clinical trial data supporting new device-drug combinations for the US market.

“This collaboration agreement with Long Grove Pharmaceuticals is a clear-cut win-win for both companies’ development strategies. The data flowing from these studies will be an invaluable resource for our regulatory submissions,” Dr. Camile Farah, Optiscan CEO.

Manufacturer’s Monthly – Read the full article here